Sanara MedTech Inc. (SMTI) Q1 2026 earnings reveal 19% revenue growth and net income of $0.4 million. Future outlook remains positive.

Key Takeaways

• Revenue for Q1 2026 reached $28.5 million, representing a 19% increase year-over-year.
• The company achieved GAAP net profitability with net income of $0.4 million, or $0.04 per diluted share.
• Operating income increased to $2.6 million, compared to $0.8 million in Q1 2025.
• Adjusted EBITDA surged by 58%, amounting to $4.3 million for the quarter.
• Full year 2026 revenue guidance remains in the range of $116 million to $121 million, indicating 13% to 17% growth.

Financial Performance

Sanara MedTech Inc. reported a robust performance for the first quarter ending March 31, 2026, showcasing significant growth and operational improvements. The company's revenue totaled $28.5 million, a 19% increase from the same quarter in the previous year. This revenue growth was primarily driven by strong sales in its soft tissue repair product lines, including Seller 8 Rx and Biosurg.

The gross profit for the quarter rose to $25.9 million, reflecting a 20% year-over-year increase. The gross margin improved to 93%, up approximately 100 basis points from the prior year. This increase was attributed to enhanced market penetration, a favorable product mix, and strategic expansion of the distribution network.

Operating expenses were reported at $23.2 million (83.6% of sales), up from $20.8 million (88.6% of sales) in Q1 2025. The increase in operating expenses was mainly due to higher selling, general, and administrative (SG&A) costs, although research and development (R&D) expenses decreased.

Strategic Initiatives

The company emphasized its focused transition towards the surgical market, which has yielded notable results. The first quarter of 2026 marked the first full quarter of this strategic shift. The company has strengthened its sales team, now comprising 43 representatives, to enhance sales capabilities and market reach.

As of the end of the quarter, Sanara's products were contracted or approved for sale in over 4,000 hospitals and ambulatory surgery centers across the U.S. This is a significant growth from 1,300 facilities a year ago, with contracts established with more than 450 distributors.

The management highlighted the importance of having a strong surgeon user network, which has seen solid growth year-over-year. This focus on surgical applications positions the company to leverage its expertise and minimize exposure to reimbursement risks, thus ensuring a reliable revenue stream.

Future Outlook

Looking ahead, Sanara MedTech remains optimistic about its growth trajectory. For the second quarter of 2026, the company anticipates net revenue between $28.5 million and $29.5 million, translating to a year-over-year growth of 10% to 14%. The full-year guidance is unchanged, reaffirming a revenue range of $116 million to $121 million.

Management is confident in the company’s ability to drive organic growth through targeted investments in R&D and an expanding product pipeline. Key products in development, such as Austication, a synthetic injectable structural bioadhesive bone void filler, are on track for market introduction in Q1 2027, further enhancing the company’s competitive edge.

The emphasis on strengthening operational efficiencies and improving free cash flow generation is expected to allow Sanara to invest strategically in its growth initiatives. Management reiterated their commitment to capital allocation strategies that prioritize organic growth and the development of innovative surgical products.

Conclusion

Sanara MedTech Inc.'s first quarter results for 2026 reflect a strong start to the year, showcasing impressive revenue growth and operational improvements as the company fully aligns with its strategic focus on the surgical market. The management's commitment to expanding its sales team and enhancing market penetration positions the company favorably for sustained growth. With an optimistic outlook and a solid foundation, Sanara MedTech appears well-equipped to navigate challenges and capitalize on opportunities in the surgical space.

This analysis is based on public earnings call materials and is not investment advice.